DRKS00010928已完成不适用
Incidence and Resolution of Eribulin-induced peripheral Neuropathy (IRENE)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Eisai GmbH
- 入组人数
- 341
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Locally advanced or metastatic breast cancer with progression after at least one chemotherapeutic regimen for advanced disease eligible for treatment with eribulin according to Fachinformation. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. (Update Protocol V1.1 13Jun17)
- •- Maximum of two prior chemotherapeutic regimens for advanced disease.
- •- Age =18 years at the time of Informed Consent.
- •- Ability to understand and willingness to respond to questions related to their health.
- •- Decision for the patient to start treatment with eribulin has been made prior to inclusion in this study.
- •- Signed written Informed Consent.
排除标准
- •- Previous treatment with eribulin in any line of treatment.
- •- Contraindication according to the Fachinformation of eribulin.
- •- Pregnancy or lactation.
- •- Participation in an interventional clinical trial at the same time
研究者
相似试验
已完成
不适用
Incidence and Resolution of Eribulin-Induced Peripheral NeuropathyLocally Advanced or Metastatic Breast CancerNCT03027245Eisai GmbH353
已完成
不适用
The analysis of Eribulin in patients with unresectable breast cancer, retorospective multicenter studyHER2-negative Unresectable breast cancerJPRN-UMIN000014158Kobe City Medical Center General Hospital150
招募中
不适用
Exploratory clinical study of eribulin followed by taxane for metastatic breast cancer patientsMetastatic breast cancerJPRN-UMIN000027527Yamaguchi University Graduate School of Medicine30
已完成
2 期
A phase 2 study of eribulin in combination with pertuzumab and trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancerJPRN-UMIN000014107SONG (South Osaka Network Group for Breast Cancer)43
已完成
2 期
Phase II trial of eribulin in patients with recurrent glioblastoma (ENIGMA)GlioblastomaJPRN-UMIN000030359ational Cancer Center38